Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q5JTZ9
UPID:
SYAM_HUMAN
Alternative names:
Alanyl-tRNA synthetase
Alternative UPACC:
Q5JTZ9; A2RRN5; Q8N198; Q96D02; Q9ULF0
Background:
Alanine--tRNA ligase, mitochondrial, also known as Alanyl-tRNA synthetase, plays a crucial role in protein synthesis. It catalyzes the attachment of alanine to tRNA(Ala), facilitating the accurate translation of genetic information into functional proteins. Additionally, it ensures the fidelity of protein synthesis through its editing domain, which corrects incorrectly charged tRNA(Ala).
Therapeutic significance:
The protein is implicated in Combined oxidative phosphorylation deficiency 8, a mitochondrial disease with severe cardiomyopathy, and in Leukoencephalopathy with ovarian failure, marked by neurodegeneration and premature ovarian failure. Understanding the role of Alanine--tRNA ligase, mitochondrial, could open doors to potential therapeutic strategies for these conditions.